24 Nov

Morgans Investment Conference Presentation

control bionics MoRGANs TECHNOLOGY CONFERENCE November 24 2021 Control Bionics Limited ABN 45 115 465 462 Morgans Technology Conference | November 24, 2021 Disclaimer 2 This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information ? in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group). While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group. The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group ? and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including Control Bionics). ? In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will ? be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation ? or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances ? create an implication that there has been no changed in the affairs of the Group since the date of these materials. Morgans Technology Conference | November 24, 2021 WHERE HAS THE BUSINESS COME FROM? Morgans Technology Conference | November 24, 2021 3 Inspired mind of our Founder and his ultimate vision to free the human inside, no matter how locked in, through wireless wearable technology connected to body. We are just beginning to understand what’s possible. Peter Ford Founder “The totally wired user” mission 4 To be the global leader ? in innovative augmentative ? communications and ? control devices Morgans Technology Conference | November 24, 2021 WoRLD CLASS AUSTRALIAN Wireless ? Wearable EMG TECHNOLOGY 5 • Leading EMG Technology • Spatial orientation technology • Low latency brain intent activation via EMG • 24hr battery • Non Invasive • Connects to speech generating software • Windows, iOS, Android • Allows locked in or compromised people to control TVs, air-conditioners, doors, computer games & robots. • Morgans Technology Conference | November 24, 2021 Creating Market WINNING ProdUCTS 6 We combined our NeuroNode wearable technology with high quality eye-gaze camera technology creating market leading products that delivered faster communication speed and significantly less fatigue than existing competition globally. Morgans Technology Conference | November 24, 2021 Morgans Technology Conference | November 24, 2021 Our Products 8 • World class patented NeuroNode technology • Two primary assistive communication technology solutions for disability sector globally Morgans Technology Conference | November 24, 2021 TECHNOLOGY ROADMAP 9 Morgans Technology Conference | November 24, 2021 2022 2023 2024 2025 2030 GloBAL GROWTH PLAN SINCE IPO Dec 2020 10 • Strategic Priorities FY21 • Increased expansion in Australian assistive technology sector • Increased expansion in North America assistive technology sector • International expansion Japan & Singapore • Investment in R&D to enhance product range & miniaturise our core NN technology Morgans Technology Conference | November 24, 2021 Exciting, SuCCESSFUL & Challenging FY21 11 • Revenue of $3.97m • Investment year with 28% YOY growth in revenue despite COVID-19 business impact • Solid growth in key regions of USA and Australia • Strong balance sheet with $12.3m in cash as at June 30th • Top 10 Financial Review Boss Most Innovative Companies - Health Industries Morgans Technology Conference | November 24, 2021 12 make a life–changing connection Morgans Technology Conference | November 24, 2021 MOMENTUM FOR the year ahead 13 Morgans Technology Conference | November 24, 2021 Significant Addressable Market (Current Focus) 14 Type to enter a caption. Morgans Technology Conference | November 24, 2021 Momentum with Senior ? Global Management Team 15 Neale Java CFO Jamie Lemsing International Development Todd Tyler Vice President North America Meagan Koeneman North America Sales Director Kristen Learning & Education Manager Annette Curry Australia Region Sales Director Alex Alvarado Product Development ? & Training Manager James Schorey CTO Peter Ford Director of Innovation – new markets Rob Wong CEO Chris Feighner Global Production ? & Quality Control Stacey Berard Funding Manager USA Morgans Technology Conference | November 24, 2021 Key Priorities 2021/22 16 • Revenue Growth • Revenue growth focus in Australia and North America through partners and sales team channels post COVID-19 • Operating Expenditure • Optimise productivity and strategic investments • Product leadership • NEW branding and marketing investment in awareness • NEW expanded product range within assistive technology market (autism) • Rental model rollout • New International Markets • Opening up of Japan market post COVID-19 • Expand presence in Singapore • International market entry post COVID (Europe & Asia) • R&D ? • Developing road map for NeuroNode wearable technology in selected markets ? • Developing wheelchair control project with Deakin University Morgans Technology Conference | November 24, 2021 ` Expanded Product Range FY 22 17 Morgans Technology Conference | November 24, 2021 New Product - Australia Launch 18 • Compact h andheld device speech generating software with detachable speaker, keyboard guides • Launched in Australia Q2, 2022 • Estimated there are 164,000 people in Australia with autism, 58% have communication disabilities, and 43,000 are registered with NDIS*. • The product is expected to complement the Control Bionics AAC range. * https://www.aihw.gov.au/reports/disability/autism-in-australia/contents/autism Morgans Technology Conference | November 24, 2021 • Allows single switch users to connect to multiple components like XBOX game consoles, feeding robots, iOS devices, Android devices and toys. • Includes Pilot Mode so users can play with friends and family ` NEW COSMOS CoNNECT PlUG-IN 19 • Expected to be a strong sales add-on for core Control Bionics AAC systems. Until now, many people in our target audience have been locked out of these life enjoying experiences. • Launch Australia and USA Q2, 2022. Morgans Technology Conference | November 24, 2021 • Extension markets for NeuroNode IP & users. More control of environment and wheelchair transport. R&D partnership with Deakin University for wheelchair control. • Taps Global $5.4B (2027), CAGR 7.3%, power wheelchair market.* innovation ROADMAP 20 Morgans Technology Conference | November 24, 2021 * marketwatch.com/press-release/electric-wheelchair -market-sizeshare-2021 innovation ROADMAP 20 • More control & monitoring applications to disability markets and beyond through miniaturisation of our technology, on the road towards the “totally wired user”. More news in Q3. • Global Medical Patient Monitoring Market $23.3B, 2020, CAGR 6.9%. Wireless segment 7.3%* • Global elderly disabled assistive devices market $23B, 2018, GAGR 5.5%** • Global wearable technology market size $40B, 2020, CAGR 13.8%*** Morgans Technology Conference | November 24, 2021 * www.gminsights.com/industry-analysis/patient-monitoring-devices-market ** www.alliedmarketresearch.com/elderly-and-disabled-assistive-devices-market ** * www.grandviewresearch.com /industry-analysis/wearable-technology-markete contact 21 Rob Wong CEO robwong@controlbionics.com +61 419238768 Brett Crowley Company Secretary brettcrowley@controlbionics.com +61 3 9897 3576 Morgans Technology Conference | November 24, 2021

More from CBL Corporation Limited


Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from CBL Corporation Limited (ASX:CBL) when you join Listcorp.